BioMarin Targets Faster Deleveraging with Amicus Deal

BioMarin is targeting faster deleveraging as its deal with Amicus expands its rare-disease growth opportunities. This strategic move aims to strengthen the company's financial position while enhancing its presence in the rare disease market.